Immune modulating nanoparticles for the treatment of ocular diseases
Abstract Ocular diseases are increasingly influencing people’s quality of life. Complicated inflammatory mechanisms involved in the pathogenic process of ocular diseases make inflammation-targeting treatment a potential therapeutic approach. The limited efficacy of conventional anti-inflammatory the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-11-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-022-01658-5 |
| _version_ | 1797986867000377344 |
|---|---|
| author | Lianfei Fang Jin Liu Zeyang Liu Huifang Zhou |
| author_facet | Lianfei Fang Jin Liu Zeyang Liu Huifang Zhou |
| author_sort | Lianfei Fang |
| collection | DOAJ |
| description | Abstract Ocular diseases are increasingly influencing people’s quality of life. Complicated inflammatory mechanisms involved in the pathogenic process of ocular diseases make inflammation-targeting treatment a potential therapeutic approach. The limited efficacy of conventional anti-inflammatory therapeutic strategies, caused by various objective factors, such as complex ocular biological barriers, and subjective factors, such as poor compliance, are promoting the development of new therapeutic methods. With the advantages of considerable tissue permeability, a controllable drug release rate, and selective tissue targeting ability, nanoparticles have successfully captured researchers’ attention and have become a research hotspot in treating ocular diseases. This review will focus on the advantages of nanosystems over traditional therapy, the anti-inflammation mechanisms of nanoparticles, and the anti-inflammatory applications of nanoparticles in different ocular diseases (ocular surface diseases, vitreoretinopathy, uveal diseases, glaucoma, and visual pathway diseases). Furthermore, by analyzing the current situation of nanotherapy and the challenges encountered, we hope to inspire new ideas and incentives for designing nanoparticles more consistent with human physiological characteristics to make progress based on conventional treatments. Overall, some progress has been made in nanoparticles for the treatment of ocular diseases, and nanoparticles have rather broad future clinical translation prospects. Graphical abstract |
| first_indexed | 2024-04-11T07:39:46Z |
| format | Article |
| id | doaj.art-8a6d1112a037422ebed7356ba05fee60 |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-11T07:39:46Z |
| publishDate | 2022-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-8a6d1112a037422ebed7356ba05fee602022-12-22T04:36:38ZengBMCJournal of Nanobiotechnology1477-31552022-11-0120113010.1186/s12951-022-01658-5Immune modulating nanoparticles for the treatment of ocular diseasesLianfei Fang0Jin Liu1Zeyang Liu2Huifang Zhou3Department of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of MedicineDepartment of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of MedicineDepartment of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of MedicineDepartment of Ophthalmology, Ninth People’s Hospital, Shanghai JiaoTong University School of MedicineAbstract Ocular diseases are increasingly influencing people’s quality of life. Complicated inflammatory mechanisms involved in the pathogenic process of ocular diseases make inflammation-targeting treatment a potential therapeutic approach. The limited efficacy of conventional anti-inflammatory therapeutic strategies, caused by various objective factors, such as complex ocular biological barriers, and subjective factors, such as poor compliance, are promoting the development of new therapeutic methods. With the advantages of considerable tissue permeability, a controllable drug release rate, and selective tissue targeting ability, nanoparticles have successfully captured researchers’ attention and have become a research hotspot in treating ocular diseases. This review will focus on the advantages of nanosystems over traditional therapy, the anti-inflammation mechanisms of nanoparticles, and the anti-inflammatory applications of nanoparticles in different ocular diseases (ocular surface diseases, vitreoretinopathy, uveal diseases, glaucoma, and visual pathway diseases). Furthermore, by analyzing the current situation of nanotherapy and the challenges encountered, we hope to inspire new ideas and incentives for designing nanoparticles more consistent with human physiological characteristics to make progress based on conventional treatments. Overall, some progress has been made in nanoparticles for the treatment of ocular diseases, and nanoparticles have rather broad future clinical translation prospects. Graphical abstracthttps://doi.org/10.1186/s12951-022-01658-5NanoparticlesOcular diseasesAnti-inflammatory mechanismsTreatment |
| spellingShingle | Lianfei Fang Jin Liu Zeyang Liu Huifang Zhou Immune modulating nanoparticles for the treatment of ocular diseases Journal of Nanobiotechnology Nanoparticles Ocular diseases Anti-inflammatory mechanisms Treatment |
| title | Immune modulating nanoparticles for the treatment of ocular diseases |
| title_full | Immune modulating nanoparticles for the treatment of ocular diseases |
| title_fullStr | Immune modulating nanoparticles for the treatment of ocular diseases |
| title_full_unstemmed | Immune modulating nanoparticles for the treatment of ocular diseases |
| title_short | Immune modulating nanoparticles for the treatment of ocular diseases |
| title_sort | immune modulating nanoparticles for the treatment of ocular diseases |
| topic | Nanoparticles Ocular diseases Anti-inflammatory mechanisms Treatment |
| url | https://doi.org/10.1186/s12951-022-01658-5 |
| work_keys_str_mv | AT lianfeifang immunemodulatingnanoparticlesforthetreatmentofoculardiseases AT jinliu immunemodulatingnanoparticlesforthetreatmentofoculardiseases AT zeyangliu immunemodulatingnanoparticlesforthetreatmentofoculardiseases AT huifangzhou immunemodulatingnanoparticlesforthetreatmentofoculardiseases |